Syncona Limited (SYNC) Ordinary NPV
Sell:99.70p
Buy:100.80p
0
Change:
No change
No change
FTSE 250:0.42%
Market closed |
Prices as at close on 22 November 2024
Prices delayed by at least 15 minutes
|
Switch to live prices
|
- Add to watchlist
- Create an alert
- This stock can be held in a
Sell:99.70p
Buy:100.80p
Change:
No change
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Market closed |
Prices as at close on 22 November 2024
Prices delayed by at least 15 minutes
|
Switch to live prices
|
Sell:99.70p
Buy:100.80p
Change:
No change
No change
Market closed |
Prices as at close on 22 November 2024
Prices delayed by at least 15 minutes
|
Switch to live prices
|
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Objective
The Company’s investment objective is to achieve superior long-term capital appreciation from its investments. The Company invests in life science businesses and single or multi-asset projects. The Company targets an annualised return per share across its investment portfolio of 15 per cent per annum over the long term.
| Security | Weight |
|---|---|
| Capital Pool | 30.81% |
| Spur Therapeutics | 13.76% |
| Beacon Therapeutics | 9.87% |
| Autolus Therapeutics PLC ADR | 7.29% |
| Quell Therapeutics | 6.99% |
| Resolution Therapeutics | 5.56% |
| Purespring Therapeutics | 4.47% |
| Omass Therapeutics | 4.34% |
| Anaveon | 3.14% |
| Crt Pioneer Fund | 2.89% |
Top 10 sectors currently unavailable.
| Country | Weight |
|---|---|
| United Kingdom | 8.03% |
| United States | 0.13% |
Fee Structure
The company will pay SIML an annual fee of up to 1.05% p.a. of the NAV of company. The fee will be payable monthly in arrears and each payment shall be calculated using the monthly NAV as at the relevant month end.
Dividend Policy
The Company has announced that it does not intend to pay an annual dividend in future years.
ASSET SPLIT
Trust Manager
Not currently available for this investment trust.
Manager Bio
Not currently available for this investment trust.
Board Of Directors
Melanie GeeChairman, Virginia Holmes, Cristina Csimma, Julie Cherrington, Gian Reverberi, Kemal Malik, Robert Hutchinson, John Roche
Data policy - All information should be used for indicative purposes only. You should
independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete,
and accepts no responsibility for how it may be used.
Objective, holding data, trust manager and bio information, dividend policy, asset split and fee structure are provided by Morningstar.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.